ArticleBMC infectious diseases2020
Global molecular diversity of RSV - the "INFORM RSV" study.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical characterization of patients and genomic description of respiratory syncytial virus in adults and paediatric patients in a northeastern Mexican population.Journal of medical microbiology · 2026Observational
- Small molecule-directed differentiation of submerged-cultured human nasal airway epithelia for respiratory disease modeling.Cell reports. Medicine · 2026Article
- Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case-control study.BMJ open · 2026Observational
- A tiled amplicon protocol for culture-free whole-genome sequencing ofJournal of clinical microbiology · 2026Article
- A review of synergistic strategies in cancer therapy: resveratrol-loaded hydrogels for targeted and multimodal treatment.Discover oncology · 2025Review
- Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024.Open forum infectious diseases · 2025Article
- Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.MedComm · 2024Review
- Whole genome molecular analysis of respiratory syncytial virus pre and during the COVID-19 pandemic in Free State province, South Africa.Virus research · 2024Article
- The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus.Nature communications · 2024Article
- Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B.Microbiology spectrum · 2024Article
- Genomic characterization of respiratory syncytial virus genotypes circulating in the paediatric population of Sydney, NSW, Australia.Microbial genomics · 2023Article
- Review
- Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections.Infectious disease reports · 2022Review
- Delayed respiratory syncytial virus outbreak in 2020 in Taiwan was correlated with two novel RSV-A genotype ON1 variants.Influenza and other respiratory viruses · 2022Article
- In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein.Emergent materials · 2022Article
- RSV Prevention in All Infants: Which Is the Most Preferable Strategy?Frontiers in immunology · 2022Review
- Genetic Diversity and Molecular Epidemiology of Circulating Respiratory Syncytial Virus in Central Taiwan, 2008-2017.Viruses · 2021Article
- Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Clinical and biological consequences of respiratory syncytial virus genetic diversity.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 16 institutions in 12 countries.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.
methodsThe INFORM study is performed in 17 countries spanning all inhabited continents and will provide insight into the molecular epidemiology of circulating RSV strains worldwide. Sequencing of > 4000 RSV-positive respiratory samples is planned to detect temporal and geographical molecular patterns on a molecular level over five consecutive years. Additionally, RSV will be cultured from a subset of samples to study the functional implications of specific mutations in the viral genome including viral fitness and susceptibility to different monoclonal antibodies. DISCUSSION: The sequencing and functional results will be used to investigate susceptibility and resistance to novel RSV preventive or therapeutic interventions. Finally, a repository of globally collected RSV strains and a database of RSV sequences will be created.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.